Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.
about
Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyProspective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patientsMechanical stress downregulates MHC class I expression on human cancer cell membraneCharacterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Exploiting natural killer cells for therapy of melanoma.Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity.Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer.When unity makes strength: Combinatorial NK cell-based immunotherapies against melanomaOncogenes in immune cells as potential therapeutic targets.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
P2860
Q26771449-F2B92F8E-083C-4D36-90F2-274FEEAD71A0Q28542660-CF8F28EB-04C3-46C6-A6D4-42AA5ED3B8B7Q30422252-6D5E49C0-991D-49CD-8E39-24C65D7FF8E6Q35719855-AACCA95E-A106-4FBB-850A-75B5407120B1Q35987354-02F71D15-430F-400E-8452-99D0ABB7AC77Q37222064-A2415F97-449A-49B8-9E70-C34BFAF37017Q37323344-00EB85B5-B8CE-4760-8B9F-053064A371F5Q37558627-835D2B86-6B1A-4B51-8A8F-D8ED678491A8Q37616478-7DE292CA-6F2D-4860-B8E9-34427987D4BAQ38339842-B68278EC-CB7C-498A-8DAB-6A2E5F52B3F2Q38394496-E739C5A6-369A-4778-9C39-8921AB2EA4CDQ38857163-7B1051B4-2B4F-4CC8-9039-48EF59B39D6BQ40348935-F98FCA5F-5AD0-460C-AD29-17A02B777495Q41333332-30A42CA9-2DA9-4AF4-8924-5ABA14558FD8Q42209070-5E671E20-2A84-4B42-88B5-A56DDAF9CA51Q42378441-80B6EBC9-A913-4D36-9C02-35FAFA931D01Q42726223-0D74F113-59E1-4062-B81F-6374F7B60E62Q52716894-11F837F4-1418-43C1-837D-E259729EC9F4Q53068034-3B156279-DE3E-4ECB-B5F3-FA4F5E9D44E6Q53772695-2ECEF7D6-5822-4C04-8686-F6DBEA0C1C17Q58766803-3C64C207-D308-4109-A574-073423C1C432
P2860
Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phenotypic and functional char ...... at different clinical stages.
@ast
Phenotypic and functional char ...... at different clinical stages.
@en
type
label
Phenotypic and functional char ...... at different clinical stages.
@ast
Phenotypic and functional char ...... at different clinical stages.
@en
prefLabel
Phenotypic and functional char ...... at different clinical stages.
@ast
Phenotypic and functional char ...... at different clinical stages.
@en
P2093
P2860
P50
P1433
P1476
Phenotypic and functional char ...... at different clinical stages.
@en
P2093
Eduardo Marinho
Emmanuelle Fourmentraux-Neves
Giulia Fregni
Isabelle Scheer-Senyarich
Johan Chanal
Marie-Françoise Avril
Sarra Mazouz-Dorval
P2860
P304
P356
10.1371/JOURNAL.PONE.0076928
P407
P577
2013-10-18T00:00:00Z